Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Cytarabine Plus Arsenic Trioxide in Elderly AML
NCT00850304Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2007
- Primary completion
- Feb 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in acute myeloid leukemia (AML), sponsored by Tehran University of Medical Sciences. Primary endpoint: Overall Response Rate at 1 year. Started Oct 2007; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00850304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00850304.